Latest period
$168.70M
YoY change
-6.3%
5Y CAGR
+6.0%
Peak year (2006)
$5.85B
Latest annual
$159.60M
Stock-Based Compensation history chart for DexCom (DXCM) from 2003 to 2025
Latest: $159.60M
Stock-Based Compensation growth chart for DexCom (DXCM) from 2003 to 2025
Latest: -6.3%
Stock-Based Compensation history table for DexCom (DXCM) from 2003 to 2025
| 2025 | $159.60M | -6.3% | −$10.80M | ||
| 2024 | $170.40M | +13.0% | +$19.60M | ||
| 2023 | $150.80M | +19.2% | +$24.30M | ||
| 2022 | $126.50M | +11.6% | +$13.10M | ||
| 2021 | $113.40M | -5.0% | −$6.00M | ||
| 2020 | $119.40M | +16.3% | +$16.70M | ||
| 2019 | $102.70M | +0.8% | +$800.00K | ||
| 2018 | $101.90M | -4.0% | −$4.30M | ||
| 2017 | $106.20M | -4.2% | −$4.60M | ||
| 2016 | $110.80M | +34.0% | +$28.10M | ||
| 2015 | $82.70M | +65.4% | +$32.70M | ||
| 2014 | $50.00M | +103.3% | +$25.40M | ||
| 2013 | $24.60M | +33.7% | +$6.20M | ||
| 2012 | $18.40M | +36.2% | +$4.89M | ||
| 2011 | $13.51M | +43.1% | +$4.07M | ||
| 2010 | $9.44M | +12.8% | +$1.07M | ||
| 2009 | $8.37M | +8.9% | +$684.00K | ||
| 2008 | $7.68M | +25.5% | +$1.56M | ||
| 2007 | $6.12M | -99.9% | −$5.85B | ||
| 2006 | $5.85B | +251.4% | +$4.19B | ||
| 2005 | $1.67B | — | +$1.67B | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | — |
- 2025$159.60M-6.3%
- 2024$170.40M+13.0%
- 2023$150.80M+19.2%
- 2022$126.50M+11.6%
- 2021$113.40M-5.0%
- 2020$119.40M+16.3%
- 2019$102.70M+0.8%
- 2018$101.90M-4.0%
- 2017$106.20M-4.2%
- 2016$110.80M+34.0%
- 2015$82.70M+65.4%
- 2014$50.00M+103.3%
- 2013$24.60M+33.7%
- 2012$18.40M+36.2%
- 2011$13.51M+43.1%
- 2010$9.44M+12.8%
- 2009$8.37M+8.9%
- 2008$7.68M+25.5%
- 2007$6.12M-99.9%
- 2006$5.85B+251.4%
- 2005$1.67B—
- 2004$0.00—
- 2003$0.00—
Stock-Based Compensation values are taken from DexCom's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at DexCom (DXCM)
Stock-Based Compensation for DexCom (DXCM): headline value $168.70M · YoY -6.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
DexCom (DXCM) most recent annual stock-based compensation stands at $159.60M (2025) – declined 6.3% year-over-year.
DexCom stock-based compensation has grown on net over the period, with a +6.0% compound annual growth rate over 2020–2025 (5 years).
Across the available history, stock-based compensation reached its high of $5.85B in 2006 and its low of $0.00 in 2003.
DexCom Stock-Based Compensation by Year
DexCom Stock-Based Compensation 2025: $159.60M
DexCom posted stock-based compensation of $159.60M in 2025, declined 6.3% below 2024.
DexCom Stock-Based Compensation 2024: $170.40M
In 2024, DexCom reported stock-based compensation of $170.40M, grew 13.0% from 2023.
DexCom Stock-Based Compensation 2023: $150.80M
DexCom stock-based compensation in 2023 was $150.80M, grew 19.2% from 2022.
DexCom Stock-Based Compensation 2022: $126.50M
2022's stock-based compensation for DexCom came in at $126.50M, grew 11.6% from 2021.
DexCom Stock-Based Compensation 2021: $113.40M
DexCom stock-based compensation in 2021 was $113.40M.
See more financial history for DexCom (DXCM).
Sector peers by Stock-Based Compensation
Healthcare peers of DexCom (DXCM), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation